WO2006104594A2 - Spiro-containing compounds and compositions as modulators of steroid hormone nuclear receptors - Google Patents
Spiro-containing compounds and compositions as modulators of steroid hormone nuclear receptors Download PDFInfo
- Publication number
- WO2006104594A2 WO2006104594A2 PCT/US2006/005803 US2006005803W WO2006104594A2 WO 2006104594 A2 WO2006104594 A2 WO 2006104594A2 US 2006005803 W US2006005803 W US 2006005803W WO 2006104594 A2 WO2006104594 A2 WO 2006104594A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- compounds
- pharmaceutically acceptable
- receptor
- Prior art date
Links
- 0 *C1(*)N*C11*(cccc2)c2Nc2c1cccc2 Chemical compound *C1(*)N*C11*(cccc2)c2Nc2c1cccc2 0.000 description 8
- RDYOFSCVQKBGTK-UHFFFAOYSA-N CC(C)(N(C1)S(C)(=O)=O)OC11c2ccccc2C=Cc2ccccc12 Chemical compound CC(C)(N(C1)S(C)(=O)=O)OC11c2ccccc2C=Cc2ccccc12 RDYOFSCVQKBGTK-UHFFFAOYSA-N 0.000 description 1
- WLNOKYCNZQEPHW-UHFFFAOYSA-N COc1ccc(C(CC2)(N(C3)C2=O)OC32c(cccc3)c3C=Cc3c2cccc3)cc1 Chemical compound COc1ccc(C(CC2)(N(C3)C2=O)OC32c(cccc3)c3C=Cc3c2cccc3)cc1 WLNOKYCNZQEPHW-UHFFFAOYSA-N 0.000 description 1
- BMVWCPGVLSILMU-UHFFFAOYSA-N O=C1c2ccccc2CCc2ccccc12 Chemical compound O=C1c2ccccc2CCc2ccccc12 BMVWCPGVLSILMU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Definitions
- Steroid hormone nuclear receptors represent a subset of the nuclear hormone receptor superfamily. So named according to the cognate ligand which complexes with the receptor in its native state, the steroid hormone nuclear receptors include the glucocorticoid receptor (GR), the androgen receptor (AR), the mineralocorticoid receptor (MR), the estrogen receptor (ER), and the progesterone receptor (PR).
- GR glucocorticoid receptor
- AR the androgen receptor
- MR mineralocorticoid receptor
- ER estrogen receptor
- PR progesterone receptor
- MR is expressed in epithelial tissues, heart, kidneys, brain, vascular tissues and bone.
- Aldosterone is the endogenous ligand of MR and is primarily synthesized in the adrenal glands, heart, brain and blood vessels.
- aldosterone Several detrimental effects are attributable to aldosterone, for example: sodium/water retention, renal fibrosis, vascular inflammation, vascular fibrosis, endothelial dysfunction, coronary inflammation, decrease in coronary blood flow, ventricular arrhythmias, myocardial fibrosis, ventricular hypertrophy and direct damage to cardiovascular systems, primarily the heart, vasculature and kidneys.
- Aldosterone action on all target organs is through activation of the MR receptor.
- GR is expressed in almost all tissues and organ systems and is crucial for the integrity of the function of the central nervous system and the maintenance of cardiovascular, metabolic, and immune homeostasis.
- compositions comprising such a compound having a spiro structure.
- methods for making such compounds having a spiro structure are provided.
- each optional substituent R 5 is independently selected from halogen, OH, NH 2 , SH, NO 2 , CN, and an optionally substituted moiety selected from -L 2 -alkyl, -L 2 -cycloalkyl, -L 2 -heteroalkyl, -L 2 -haloalkyl, -L 2 -aryl, -L 2 - heterocycloalkyl, or -L 2 -heteroaryl, wherein L 2 is selected from a bond, O, NH, S, -C(O)-, - C(S)-, -C(O)O-, -C(O)NH-, -S(O)-, -S(O) 2 ,
- X is O, NR 7 , C(Rg) 2 , or S;
- Ri is H, or an optionally substituted moiety selected from -Li-alkyl, -Li -cycloalkyl, - Li-heteroalkyl, -Li-haloalkyl, -Li-aryl, -Li-heterocycloalkyl, and -Li -heteroaryl, wherein Li is selected from a bond, -C(O)-, -C(S)-, -C(O)O-, -C(O)NH-, -S(O)-, -S(O) 2 , and -S(O)NH-; wherein said optional substituents of an Ri moiety are selected from halogen,
- R 2 and R 3 are independently selected from H, halogen, OH, NH 2 , SH, NO 2 , CN, and an optionally substituted moiety selected from -L 2 -alkyl, - L 2 -cycloalkyl, -L 2 -heteroalkyl, -L 2 -haloalkyl, -L 2 -ETyI, -L 2 -heterocycloalkyl, and -L 2 -heteroaryl, wherein L 2 is selected from a bond, O, NH, S, -C(O)-, -C(S)-, -C(O)O-, -C(O)NH-, -S(O)-, - S(O) 2 , and -S(O)NH-; wherein said optional substituents of an R 2 OrR 3 moiety are selected from H, halogen, OH, NH 2 , SH, NO 2 , CN, and an optionally substituted
- X is O and Z is C(R 6 ⁇ -C(Rg) 2 .
- hi a further or alternative embodiment of this aspect A is NRrCR 2 R 3 .
- hi a further or alternative embodiment of this aspect A is NRi-CR 2 Ra, and X is O.
- NR1-CR2R 3 X is O, and wherein Z is C(Re) 2 -C(Rg) 2 .
- X is O, and Ri and R 2 together form a 3 to 8-membered heterocyclic ring.
- A is NRi-CR 2 R 3 , and R 2 and R 3 together form an optionally substituted 3 to 8-membered carbocyclic or heterocyclic ring, hi a further or alternative embodiment, X is O.
- Z is C(Ro) 2 -C(Re) 2 .
- hi a further or alternative embodiment, Ri is not H.
- X is O.
- Z is C(R 6 )2-C(R 6 ) 2 .
- NRi-CR 2 R 3 and Ri is not H.
- NRi-CR 2 R 3 and R ⁇ and R 2 together form a 3 to 8-membered heterocyclic ring, hi a further or alternative embodiment of this aspect A is NRi-CR 2 R 3 , and X is O.
- X is O
- a further or alternative embodiment of this aspect A is
- X is O
- Z is C(R 6 ) 2 -C(R 6 ) 2 .
- A is NR 1 -CR 2 R 3 , and R 2 and R 3 together form an optionally substituted 3 to 8-membered carbocyclic or heterocyclic ring.
- X is O.
- Z is
- CR 6 CR 6 .
- Z is C(Re) 2 -C(Re) 2 .
- Ri is not H.
- n 0, 1, 2, 3, 4 or 5.
- methods for modulating the activity of at least one steroid hormone nuclear receptor comprising contacting at least one steroid hormone nuclear receptor with a compound having the structure of Formula (1), or a pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof.
- the compound directly contacts at least one steroid hormone nuclear receptor.
- compositions comprising at least one compound having the structure of Formula (1), or a pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, in admixture with one or more suitable excipients.
- the one or more excipients are suitable for parenteral administration.
- the one or more excipients are suitable for oral administration.
- the one or more excipients are suitable for ophthalmic administration.
- a disease or condition in an animal in which modulation of steroid hormone nuclear receptor activities can prevent, inhibit or ameliorate the pathology and/or symptoms of the disease or condition, which method comprises administering to the animal a therapeutically effective amount of a compound of Formula (1), or a pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof.
- the steroid hormone nuclear receptor is selected from the group consisting of a glucocorticoid receptor, a mineralocorticoid receptor, an androgen receptor, an estrogen receptor, and a progesterone receptor.
- the method further comprises administration of a therapeutically effective amount of second substance, wherein the second substance is used in the treatment of a disease or condition selected from the group consisting of hypokalemia, hypertension, congestive heart failure, renal failure, in particular chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart disease, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction.
- a disease or condition selected from the group consisting of hypokalemia, hypertension, congestive heart failure, renal failure, in particular chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart disease, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction.
- the substance is selected from the group consisting of an anti-obesity agent, an anti-hypertensive agent, an inotropic agent, an hypolipidemic agent, an angiotensin converting enzyme (ACE) inhibitor, an inhibitor of the Na- K-ATPase membrane pump, an neutralendopeptidase (NEP) inhibitor, an ACE/NEP inhibitor, an angiotensin II antagonist, a ⁇ -adrenergic receptor blocker, an inotropic agent, a calcium channel blocker, and a 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMG-CoA) inhibitor.
- the compound of Formula (1) is administered prior to the second substance.
- the compound of Formula (1) is administered with the second substance.
- the compound of Formula (1) is administered after the second substance.
- a compound of Formula (1) in the manufacture of a medicament for treating a disease or condition in an animal in which steroid hormone nuclear receptor activity contributes to the pathology and/or symptoms of the disease or condition.
- the steroid hormone nuclear receptor is selected from the group consisting of a glucocorticoid receptor, a mineralocorticoid receptor, an androgen receptor, an estrogen receptor, and a progesterone receptor.
- X is O
- the electrophilic reactant is selected from an acid chloride, an anhydride, an isocyanate, an isothiocyanate, or a sulfonyl chloride.
- X is O.
- X is O.
- alkenyl group refers to a hydrocarbon chain having one or more double bonds therein.
- the double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group.
- Suitable alkenyl groups include, but are not limited to, (C 2 -Cg)alkenyl groups, such as vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, 4-(2-methyl-3-butene)-pentenyl.
- the alkenyl moiety may be branched, straight chain, or cyclic (in which case, it would also be known as a "cycloalkenyl" group), and can be unsubstituted or substituted.
- alkoxy as used herein, includes -O-(alkyl), where alkyl is as defined herein.
- C 1-6 alkoxy includes, but is not limited to, methoxy, ethoxy, and the like.
- An alkoxy group can be unsubstituted or substituted.
- alkyl refers to a hydrocarbon group having from 1 to 10 carbon atoms and can include straight, branched, cyclic, saturated and/or unsaturated features.
- a numerical range such as “1 to 10” refers to each integer in the given range; e.g., “1 to 10 carbon atoms” or “Ci -1 O” or “(Ci-C 1O )” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated.
- the alkyl moiety may be a "saturated alkyl” group, which means that it does not contain any alkene or alkyne moieties.
- Representative saturated alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-l -propyl, 2-methyl- 2- ⁇ ropyl, 2-methyl-l -butyl, 3 -methyl- 1 -butyl, 2-methyl-3 -butyl, 2,2-dimethyl-l -propyl, 2- methyl-1-pentyl, 3-methyl-l-pentyl, 4-methyl-l- ⁇ entyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4- methyl-2-pentyl, 2,2-dimethyl-l-butyl, 3,3-dimethyl-l-butyl, 2-ethyl-l -butyl, butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl, and longer alkyl
- alkyl moiety may also be an "unsaturated alkyl” moiety, which means that it contains at least one alkene or alkyne moiety.
- alkene refers to a group consisting of at least two carbon atoms and at least one carbon-carbon double bond, and an
- alkyne moiety refers to a group consisting of at least two carbon atoms and at least one carbon- carbon triple bond.
- Representative unsaturated alkyl groups include, but are not limited to, ethenyl, propenyl, butenyl and the like.
- An alkyl group can be unsubstituted or substituted.
- Substituted alkyl groups include, but are not limited to, halogen-substituted alkyl groups, such as, by way of example only, trifluoromethyl, pentafiuoroethyl, and the like.
- x 2
- the alkyl groups, taken together, can optionally form a cyclic ring system and further when x 2, the alkyl groups can be the same or different.
- An alkylamine group can be unsubstituted or substituted.
- alkynyl refers to a hydrocarbon chain having one or more triple bonds therein.
- alkynyl groups include, but are not limited to, (C 2 -C 6 )alkynyl groups, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, 4-methyl-l-butynyl, 4-propyl-2-pentynyl, and 4-butyl-2-hexynyl.
- the alkynyl moiety may be branched or straight chain, and can be unsubstituted or substituted.
- amide refers to a chemical moiety with formula -C(O)NHR or -NHC(O)R, where R is selected from the group consisting of alkyl, cycloalkyl, aryl, and heterocyclic (bonded through a ring carbon).
- Amides can be formed from any amine or carboxyl side chain on the compounds described herein.
- the procedures and specific groups to make such amides are known to those of skill in the art and can readily be found in reference sources such as Greene and Wuts, Protective Groups in Organic Synthesis, 3 rd Ed., John Wiley & Sons, New York, NY, 1999, which is incorporated herein by reference in its entirety.
- aromatic refers to a closed ring structure which has at least one ring having a conjugated pi electron system and includes both carbocyclic aryl and heterocyclic aryl (or “heteroaryl” or “heteroaromatic") groups.
- the carbocyclic or heterocyclic aromatic group may contain from 5 to 20 ring atoms.
- the term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups.
- An aromatic group can be unsubstituted or substituted.
- aryloxy as used herein, includes -O-aryl group, wherein aryl is as defined herein. An aryloxy group can be unsubstituted or substituted.
- bond refers to a covalent bond between two atoms, either of which may be part of a larger moiety.
- carbocyclic or “cycloalkyl”, as used herein, refer to a compound which contains one or more covalently closed ring structures, and that the atoms forming the backbone of the ring are all carbon atoms. Such a group may have from 3 to 20 ring carbon atoms and be saturated, partially unsaturated, or fully unsaturated monocyclic, fused bicyclic, spirocyclic, bridged polycyclic or polycyclic ring comprising carbon and hydrogen atoms.
- Carbocyclic alkyl groups include, but are not limited to, cyclopropyl, cyclobutyL cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- a carbocyclic aromatic group includes, but is not limited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties such as, by way of example only, dibenzosuberenone, and dibenzosuberone.
- a carbocyclic group can be unsubstituted or substituted.
- esters refers to a chemical moiety with formula -COOR, where R is selected from the group consisting of alkyl, cycloalkyl, aryl, and heterocyclic (bonded through a ring carbon). Any hydroxy or carboxyl side chain on the compounds described herein can be esterified.
- the procedures and specific groups to make such esters are known to those of skill in the art and can readily be found in reference sources such as Greene and Wuts, Protective Groups in Organic Synthesis, 3 rd Ed., John Wiley & Sons, New York, NY, 1999, which is incorporated herein by reference in its entirety.
- An ester group can be unsubstituted or substituted.
- heteroalkyl “heteroalkenyl” and “heteroalkynyl”, as used herein, include optionally substituted alkyl, alkenyl and alkynyl moieties and which have one or more skeletal chain atoms selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof.
- a “heteroalkyl” “heteroalkenyl” and “heteroalkynyl” group can be unsubstituted or substituted.
- heteroaryl or, alternatively, “heteroaromatic”, as used herein, refers to an aryl group that includes one or more ring heteroatoms selected from nitrogen, oxygen, sulfur.
- an N-containing “heteroaromatic” or “heteroaryl” moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom.
- a polycyclic heteroaryl group may be fused or non-fused.
- a heteroaryl group can be unsubstituted or substituted.
- heterocyclic refers to ring structures in which the ring backbone contains at least one atom selected from nitrogen, oxygen, and sulfur.
- heterocyclic aromatic groups include, but are not limited to, acridinyl, benzo[l,3]dioxole, benzimidazolyl, benzindazolyl, benzoisooxazolyl, benzokisazolyl, benzofuranyl, benzofurazanyl, benzopyranyl, benzothiazolyl, benzo[b]thienyl, benzothiophenyl, benzothiopyranyl, benzotriazolyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, furazanyl, furopyridinyl, furyl, imidazolyl, indazolyl, indolyl, indolidinyl, indolizinyl, is
- a heterocyclic group can be unsubstituted or substituted.
- non-aromatic heterocyclic groups include, but are not limited to, are azepinyl, azepan-2-onyl, azetidinyl, diazepinyl, dihydrofuranyl, dihydropyranyl, dihydrothienyl, dioxanyl, dioxolanyl, l,4-dioxa-8-aza-spiro[4.5]dec-8-yl, dithianyl, ditliiolanyl, homopiperidinyl, imidazolinyl, imidazolidinyl, indolinyl, indolyl, morpholinyl, oxazepinyl, oxepanyl, oxetanyl, oxylanyl, piperidino, piperidyl, piperidiiionyl, piperazinyl, pyranyl, pyranyl
- halogen means fluoro, chloro, bromo or iodo. Preferred halogen groups are fluoro, chloro and bromo.
- haloalkyl means fluoro, chloro, bromo or iodo. Preferred halogen groups are fluoro, chloro and bromo.
- haloalkyl means fluoro, chloro, bromo or iodo. Preferred halogen groups are fluoro, chloro and bromo.
- haloalkyl haloalkenyl
- haloalkynyl haloalkoxy
- membered ring can embrace any cyclic structure.
- the term “membered” is meant to denote the number of skeletal atoms that constitute the ring.
- cyclohexyl, pyridine, pyran and thiopyran are 6-membered rings and cyclopentyl, pyrrole, furan, and thiophene are 5-membered rings.
- moiety refers to a specific segment or functional group of a molecule. Chemical moieties are often recognized chemical entities embedded in or appended to a molecule.
- protecting group refers to a chemical moiety which blocks some or all reactive moieties and prevent such groups from participating in chemical reactions until the protective group is removed.
- reactant refers to a nucleophile or electrophile used to create covalent linkages.
- sulfonyl refers to the presence of a sulfur atom, which is optionally linked to another moiety such as an alkyl group, an aryl group, or a heterocyclic group.
- Aryl or alkyl sulfonyl moieties have the formula -SO 2 R', wherein R' is alkyl or aryl as defined herein, and include, but are not limited to, methylsulfonyl, ethylsulfonyl and phenylsulfonyl groups.
- a sulfonyl group can be unsubstituted or substituted.
- a phenylsulfonyl is optionally substituted with 1 to 3 substituents independently selected from halogen, alkyl, and alkoxy.
- substituents independently selected from halogen, alkyl, and alkoxy.
- substituent is a group that may be substituted with one or more group(s) individually and independently selected from, for example, alkenyl, alkyl, alkoxy, alkylamine, alkylthio, alkynyl, amide, amino, including mono- and di-substituted amino groups, aryl, aryloxy, arylthio, carbonyl, carbocyclic, cyano, cycloalkyl, halogen, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, heterocyclic, hydroxy, isocyanato, isothiocyanato, mercapto, nitro, O-carbamyl, N-carbamyl, O-thioc
- agonist refers to a molecule such as a compound, a drug, an enzyme activator or a hormone modulator which enhances the activity of another molecule or the activity of a receptor site.
- the term "antagonist”, as used herein, refers to a molecule such as a compound, a drug, an enzyme inhibitor, or a hormone modulator, which diminishes, or prevents the action of another molecule or the activity of a receptor site.
- carrier refers to relatively nontoxic chemical compounds or agents that facilitate the incorporation of a compound into cells or tissues.
- co-administration or the like, as used herein, are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different time.
- an “effective amount” or “therapeutically effective amount”, as used herein, refer to a sufficient amount of an agent or a compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
- an “effective amount” for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in a disease.
- An appropriate “effective” amount in any individual case may be determined using techniques, such as a dose escalation study.
- the terms “enhance” or “enhancing”, as used herein, means to increase or prolong either in potency or duration a desired effect.
- the term “enhancing” refers to the ability to increase or prolong, either in potency or duration, the effect of other therapeutic agents on a system.
- An “enhancing-effective amount,” as used herein, refers to an amount adequate to enhance the effect of another therapeutic agent in a desired system.
- metabolite refers to a derivative of a compound which is formed when the compound is metabolized.
- active metabolite refers to a biologically active derivative of a compound that is formed when the compound is metabolized.
- cytochrome P450 catalyzes a variety of oxidative and reductive reactions while uridine diphosphate glucuronyltransferases catalyze the transfer of an activated glucuronic-acid molecule to aromatic alcohols, aliphatic alcohols, carboxylic acids, amines and free sulpliydryl groups.
- module means to interact with a target either directly or indirectly so as to alter the activity of the target, including, by way of example only, to enhance the activity of the target, to inhibit the activity of the target, to limit the activity of the target, or to extend the activity of the target.
- modulator refers to a molecule that interacts with a target either directly or indirectly.
- the interactions include, but are not limited to, the interactions of an agonist and an antagonist.
- pharmaceutically acceptable refers a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively nontoxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
- pharmaceutically acceptable salt of a compound, as used herein, refers to a salt that is pharmaceutically acceptable.
- the term "pharmaceutical combination” as used herein, means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients.
- the term "fixed combination” means that the active ingredients, e.g. a compound of Formula (1) and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage.
- the term “non-fixed combination” means that the active ingredients, e.g. a compound of Formula (1) and a co-agent, are administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific intervening time limits, wherein such administration provides effective levels of the two compounds in the body of the patient.
- cocktail therapy e.g.
- composition refers to a mixture of an active compound with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.
- a "prodrug”, as used herein, refers to a drug or compound in which metabolic processes within the body converts the drug or compound into a pharmacological active form.
- the term “subject” or “patient” encompasses mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
- non-mammals include, but are not limited to, birds, fish and the like.
- the mammal is a human.
- the terms "treat,” “treating” or “treatment”, as used herein, include alleviating, abating or ameliorating a disease or condition symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition.
- MR Mineralocorticoid receptor
- Elevations in aldosterone levels, or excess stimulation of mineralocorticoid receptors are linked to several pathological conditions or pathological disease states including, Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Barter's Syndrome, congestive heart failure (CHF), and conditions associated with excess catecholamine levels.
- Conn's Syndrome primary and secondary hyperaldosteronism
- increased sodium retention increased magnesium and potassium excretion (diuresis)
- diuresis increased water retention
- hypertension isolated systolic and combined systolic/diastolic
- arrhythmias myocardial fibrosis
- myocardial infarction Barter's Syndrome
- CHF
- MR expression in the brain appears to play a role in the control of neuronal excitability, in the negative feedback regulation of the hypothalamic- pituitary- adrenal axis, and in the cognitive aspects of behavioral performance.
- mineralocorticoid receptors, and modulation of MR activity are involved in anxiety and major depression.
- expression of MR may be related to differentiation of breast carcinomas.
- MR Glucocorticoid receptor
- Glucocorticoids a class of corticosteroids, are endogenous hormones with profound effects on the immune system and multiple organ systems. They suppress a variety of immune and inflammatory functions by inhibition of inflammatory cytokines such as IL-I, IL-2, IL-6, and TNF, inhibition of arachidonic acid metabolites including prostaglandins and leukotrienes, depletion of T-lymphocytes, and reduction of the expression of adhesion molecules on endothelial cells, hi addition to these effects, glucocorticoids stimulate glucose production in the liver and catabolism of proteins, play a role in electrolyte and water balance, reduce calcium absorption, and inhibit osteoblast function.
- inflammatory cytokines such as IL-I, IL-2, IL-6, and TNF
- arachidonic acid metabolites including prostaglandins and leukotrienes
- depletion of T-lymphocytes depletion of T-lymphocytes
- GR is expressed in almost all tissues and organ systems and is crucial for the integrity of the function of the central nervous system and the maintenance of cardiovascular, metabolic, and immune homeostasis.
- Glucocorticoids e. g. Cortisol, corticosterone, and cortisone
- the glucocorticoid receptor have been implicated in the etiology of a variety of pathological conditions or pathologic disease states.
- Cortisol hypo-secretion is implicated in the pathogenesis of diseases resulting in muscle weakness, increased melanin pigmentation of the skin, weight loss, hypotension, and hypoglycemia.
- glucocorticoids has been correlated to Cushing's Syndrome and can also result in obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, and polydipsia.
- Compounds which selectively modulate GR would be of clinical importance in the treatment of or prevention of a variety of diseases and conditions, including, but not limited to, inflammation, tissue rejection, auto-immunity, malignancies such as leukemias and lymphomas, Cushing's syndrome, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Thl/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypocalcaemia, hyperglycemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, Little's syndrome, inflammatory bowel disease, systemic lupus erythe
- Androgens bind to a specific receptor, the androgen receptor (AR), inside the cells of target tissues.
- the AR is expressed in numerous tissues of the body and is the receptor through which the physiological as well as the pathophysiological effects of endogenous androgen ligands, such as testosterone (T) and dihydrotestosterone (DHT), are expressed.
- the AR is composed of three main functional domains: the ligand binding domain (LBD), the DNA- binding domain, and amino-terminal domain.
- LBD ligand binding domain
- a compound that binds to the AR and mimics the effects of an endogenous AR ligand is referred to as an AR agonist, whereas a compound that inhibits the effects of an endogenous AR ligand is termed an AR antagonist.
- Binding of androgen to the receptor activates it and causes it to bind to DNA binding sites adjacent to target genes. From there it interacts with coactivator proteins and basic transcription factors to regulate the expression of the gene. Thus, via its receptor, androgens cause changes in gene expression in cells. These changes ultimately have consequences on the metabolic output, differentiation or proliferation of the cell that are visible in the physiology of the target tissue.
- Compounds which selectively modulate AR would be of clinical importance in the treatment of or prevention of a variety of diseases and conditions, including, but not limited to, prostate cancer, benign prostatic hyperplasia, hirsutism in women, alopecia, anorexia nervosa, breast cancer, acne, musculoskeletal conditions, such as bone disease, hematopoietic conditions, neuromuscular disease, rheumatological disease, wasting disease, cancer, AIDS, cachexia, for hormone replacement therapy (HRT), employed in male contraception, for male performance enhancement, for male reproductive conditions, and primary or secondary male hypogonadism.
- HRT hormone replacement therapy
- Estrogens play important roles in the development and homeostasis of the reproductive, central nervous, skeletal, and cardiovascular systems of both males and females.
- the estrogen receptor (ER) is expressed in a number of tissues including prostate, bladder, ovary, testis, lung, small intestine, vascular endothelium, and various parts of the brain.
- Compounds which selectively modulate ER would be of clinical importance in the treatment of or prevention of a variety of diseases and conditions, including, but not limited to, prostate cancer, testicular cancer, ovarian cancer, lung cancer, cardiovascular diseases, neurodegenerative conditions, urinary incontinence, CNS conditions, multiple sclerosis, GI tract conditions, osteoporosis, bone loss, bone fractures, osteoporosis, Paget's disease, abnormally increased bone turnover, periodontal disease, tooth loss, rheumatoid arthritis, osteoarthritis, periprosthetic osteolysis, osteogenesis imperfecta, metastatic bone disease, hypercalcemia of malignancy, and multiple myeloma, cartilage degeneration, endometriosis, uterine fibroid disease, breast cancer, uterine cancer, hot flashes, impairment of cognitive function, cerebral degenerative conditions, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity and incontinence.
- diseases and conditions including, but not limited to
- Progesterone receptor is a steroid hormone known primarily for its role in development and maintenance of the reproductive system. Progesterone is the natural ligand for the PR and when bound a receptor/ligand complex is formed. This complex binds to specific gene promoters present in the cell's DNA and modulates the production of mRNA and protein encoded by that gene. Synthetic ligands for PR can be agonists, which mimic the action of the natural hormone, or they can be antagonists, which inhibits the effect of the hormone. [0079] Progesterone has been implicated in a wide range of biological processes outside of the reproductive tract, hi the peripheral nervous system progesterone promotes niyelination of regenerating nerves.
- Progesterone is synthesized by Schwann cells (the cell type which produces myelin), and PR has been detected in primary Schwann cell cultures from rats, suggesting the presence of an autocrine loop. Progesterone appears to promote myelin formation by binding to PR and stimulating transcription of the transcription factor Krox-20, which in turn stimulates transcription of several myelin protein genes. Thus, both local and systemic production of progesterone may contribute to neurofibroma growth. Therefore, compounds which selectively modulate PR would be of clinical importance in the treatment of or prevention of a variety of diseases and conditions, including, but not limited to, hormone dependent breast cancers, uterine and ovarian cancers, non-malignant chronic diseases and conditions such as fibroids, hormone dependent prostate cancer, and in hormone replacement therapy. Compounds
- Compounds of Formula (A), pharmaceutically acceptable salts, pharmaceutically acceptable N-oxides, pharmaceutically active metabolites, pharmaceutically acceptable prodrugs, and pharmaceutically acceptable solvates thereof, modulate the activity of steroid hormone nuclear receptors and, as such, are useful for treating diseases or conditions in which aberrant steroid hormone nuclear receptor activity contributes to the pathology and/or symptoms of a disease or condition.
- the ring structures of P t and P 2 are independently selected from optionally substituted cycloalkyl, heterocycloalkyl, aryl, and heteroaryl.
- the ring structures of Pj and P 2 are independently comprised of 5 to 8 atoms.
- each R 5 is independently selected from halogen, OH 5 NH 2 , SH, NO 2 , CN, and an optionally substituted moiety selected from -I ⁇ -alkyl, -L 2 - cycloalkyl, -L 2 -heteroalkyl, -L 2 -haloalkyl, -L 2 -aryl, - ⁇ -heterocycloalkyl, and -L 2 -heteroaryl, wherein L 2 is selected from a bond, O, NH, S, -C(O)-, -C(S)-, -C(O)O-, -C(O)NH-, -S(O)-, - S(O) 2 , and -S(O)NH-, and each m is independently selected from 0, 1, 2, 3, 4, 5, and 6.
- the ring structure P 3 of compounds of Formula (A) is a spiro structure comprised of 5, 6, 7, or 8 atoms, and structure X, wherein X is selected from O, NR 7 , C(Rs) 2 , and S.
- the substituents R 2 and R 3 are independently selected from H, halogen, OH, NH 2 , SH, NO 2 , CN, and an optionally substituted moiety selected from -L 2 -alkyl, -L 2 -cycloalkyl, -L 2 - heteroalkyl, -L 2 -haloalkyl, -L 2 -aryl, -1 ⁇ -heterocycloalkyl, and -L 2 -heteroaryl, wherein L 2 is selected from a bond, O, NH, S, -C(O)-, -C(S)-, -C(O)O-, -C(O)NH-, -S(O)-, -S(O) 2 , and - S(O)NH-; or the substituents Ri and R 2 together form an optionally substituted 3 to 8-membered heterocyclic ring; or the substituents R 2 and R 3 together form an optionally substituted 3 to 8
- Each R 7 and Rg are independently selected from H and (Ci-C 4 )alkyl.
- the ring structure P 3 may be further substituted with two R 4 groups, wherein each R 4 is independently selected from H, halogen, OH, NH 2 , SH, NO 2 , CN, and an optionally substituted moiety selected from -L 2 -alkyl, -L 2 -cycloalkyl, -L 2 -heteroalkyl, -L 2 -haloalkyl, -L 2 - aryl, -La-heterocycloalkyl, and -L2-heteroaryl, wherein L 2 is selected from a bond, O, NH, S, - C(O)-, -C(S)-, -C(O)O-, -C(O)NH-, -S(O)-, -S(O) 2 , and -S(O)NH-, as long as at least one R 4 is
- Formula (A) Additional embodiments of Formula (A) are shown below as Formula (B), Formula (C), Formula (E), Formula (F), Formula (G), Formula (H), Formula (I), Formula (J), Formula (K), Formula (1), Formula (2), Formula (4), Formula (5), and Formula (6).
- the starting material used for the synthesis of the compounds of Formula (1) and compounds having the structures described in the prior section as described herein can be obtained from commercial sources, such as Aldrich Chemical Co. (Milwaukee, Wis.), Sigma Chemical Co. (St. Louis, Mo.), or the starting materials can be synthesized.
- the compounds described herein, and other related compounds having different substituents can be synthesized using techniques and materials known to those of skill in the art, such as described, for example, in March, ADVANCED ORGANIC CHEMISTRY 4 th Ed., (Wiley 1992); Carey and Sundberg, ADVANCED ORGANIC CHEMISTRY 4 th Ed., VoIs.
- Groups such as trityl, dimethoxytrityl, acetal and t- butyldimethylsilyl are acid labile and may be used to protect carboxy and hydroxy reactive moieties in the presence of amino groups protected with Cbz groups, which are removable by hydrogenolysis, and Fmoc groups, which are base labile.
- Carboxylic acid and hydroxy reactive moieties may be blocked with base labile groups such as, but not limited to, methyl, ethyl, and acetyl in the presence of amines blocked with acid labile groups such as t-butyl carbamate or with carbamates that are both acid and base stable but hydrolytically removable.
- Carboxylic acid and hydroxy reactive moieties may also be blocked with hydrolytically removable protective groups such as the benzyl group, while amine groups capable of hydrogen bonding with acids may be blocked with base labile groups such as Fmoc.
- Carboxylic acid reactive moieties may be protected by conversion to simple ester compounds as exemplified herein, or they may be blocked with oxidatively-removable protective groups such as 2,4-dimethoxybenzyl, while co-existing amino groups may be blocked with fluoride labile silyl carbamates.
- Allyl blocking groups are useful in then presence of acid- and base- protecting groups since the former are stable and can be subsequently removed by metal or pi-acid catalysts.
- an allyl-blocked carboxylic acid can be deprotected with a Pdo-catalyzed reaction in the presence of acid labile t-butyl carbamate or base-labile acetate amine protecting groups.
- Yet another form of protecting group is a resin to which a compound or intermediate maybe attached. As long as the residue is attached to the resin, that functional group is blocked and cannot react. Once released from the resin, the functional group is available to react.
- blocking/protecting groups may be selected from: allyl Bn Cbz alloc Me
- Compounds of Formula (A) can be synthesized according to reaction Scheme 1, wherein the initial tri-cyclic starting material comprises a reactive center (G) used to form di- micleophilic compounds, which are further reacted with various electrophilic reagents to create spiro-containing compounds.
- G reactive center
- TMSCN trimethylsilyl cyanide
- di-nucleophilic suberenone compounds (3 a) is shown, by way of example only, in reaction Scheme 3.
- the tri-cyclic starting material is an optionally substituted dibenzosuberenone compound.
- di-nucleophilic suberone compounds (3b) is shown, by way of example only, in reaction Scheme 4.
- the tri-cyclic starting material is an optionally substituted dibenzosuberone compound.
- compounds of Formula (D) in which X is S may be synthesized, by way of example only, according to reaction Scheme 5.
- Starting material such as, by way of example only, optionally substituted dibenzosuberenone or optionally substituted dibenzosuberone, react with a suitable reagent, such as, byway of example only, Lawesson's reagent, to form the thioketone compound, which is treated with a suitable cyano nucleophilic reagent, such as, by way of example only, HCN, to form the cyano/thiol compound.
- a suitable cyano nucleophilic reagent such as, by way of example only, HCN
- compounds of Formula (D) in which X is N may be synthesized, according to the exemplary reaction Scheme 6.
- Starting material such as, by way of example only, optionally substituted dibenzosuberenone or optionally substituted dibenzosuberone, react with a suitable reagent, such as, by way of example only, hydroxylamine, to form the oxime compound.
- the oxime compound reacts with a suitable cyano nucleophilic reagent, such as, by way of example only, HCN, and then is treated with a suitable reducing reagent, such as, by way of example only, lithium aluminum hydride, to afford the di-amino compound.
- the intermediate compounds of Formula (D), including, but not limited to, compound (3a) and compound (3b), maybe used to synthesize compounds of Formula (A) and structurally similar compounds disclosed herein.
- a non-limiting synthetic scheme for the formation of fused-ring spiro-compounds of Formula (C) is shown in reaction Scheme 7, wherein the di-nucleophilic compound (D) reacts with a keto-acid to generated the fused-ring spiro-compound (2) via a cyclocondensation reaction.
- X is O, X is O,
- Pi and P 2 are optiona Hy substituted Pi and Pj are optionally substituted benzene rings benzene ⁇ ngs
- P] and P 2 are optionally substituted Pi and P 2 are optionally substituted benzene ⁇ ngs benzene ⁇ ngs
- oxazolidme spiro compounds of Formula (A) is shown in scheme 11, wherein the di-nucleophilic compound (D) reacts with a ketone compound to afford the oxazolidine spiro compound (E).
- Substituted oxazolidine spiro compounds of Formula (A) may be synthesized by reaction of oxazolidine spiro compounds (E) with acid chlorides, anhydrides, isocyanates, isothiocyanates, or sulfonyl chlorides, or the like, to give the substituted oxazolidme spiro compounds (F), also shown in reaction Scheme 11 as a non-limiting example..
- Scheme 11 use eitlier an acid chloride, or an anhydride, or an isocyanate, or an isotliiocyanate, or a sulfonyl clilo ⁇ de wherein, X is O wherein, X is 0
- Compounds of Formula (1) can be prepared as a pharmaceutically acceptable salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, for example an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base, hi addition, the salt forms of the disclosed compounds can be prepared using salts of the starting materials or intermediates.
- a metal ion for example an alkali metal ion, an alkaline earth ion, or an aluminum ion
- the salt forms of the disclosed compounds can be prepared using salts of the starting materials or intermediates.
- Compounds of Formula ( 1 ) can be prepared as a pharmaceutically acceptable acid addition salt (which is a type of a pharmaceutically acceptable salt) by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, Q-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanes
- compounds of Formula (1) can be prepared as a pharmaceutically acceptable base addition salts (which is a type of a pharmaceutically acceptable salt) by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base, including, but not limited to organic bases such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like and inorganic bases such as aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.
- organic bases such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like
- inorganic bases such as aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.
- a reference to a pharmaceutically acceptable salt includes the solvent addition forms or crystal forms thereof, particularly solvates or polymorphs.
- Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of compounds of Formula (1) can be conveniently prepared or formed during the processes described herein.
- hydrates of compounds of Formula (1) can be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents including, but not limited to, dioxane, tetrahydrofuran or methanol.
- organic solvents including, but not limited to, dioxane, tetrahydrofuran or methanol.
- the compounds provided herein can exist in unsolvated as well as solvated forms, m general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
- Compounds of Formula (1) include crystalline forms, also known as polymorphs. Polymorphs include the different crystal packing arrangements of the same elemental composition of a compound.
- Polymorphs usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Various factors such as the recrystallization solvent, rate of crystallization, and storage temperature may cause a single crystal form to dominate.
- Compounds of Formula (1) in unoxidized form can be prepared from N-oxides of compounds of Formula (1) by treating with a reducing agent, such as, but not limited to, sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like in a suitable inert organic solvent, such as, but not limited to, acetonitrile, ethanol, aqueous dioxane, or the like at 0 to 80 0 C.
- a reducing agent such as, but not limited to, sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like
- a suitable inert organic solvent such as, but not limited to, acetonitrile, ethanol, aqueous dioxane, or the like at 0 to 80 0 C.
- Prodrugs are generally drug precursors that, following administration to a subject and subsequent. absorption, are converted to an active, or a more active species via some process, such as conversion by a metabolic pathway. Some prodrugs have a chemical group present on the prodrug that renders it less active and/or confers solubility or some other property to the drug. Once the chemical group has been cleaved and/or modified from the prodrug the active drug is generated. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug.
- prodrug a compound of Formula (1) which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial.
- prodrug a compound of Formula (1) which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial.
- a further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety.
- Prodrugs may be designed as reversible drug derivatives, for use as modifiers to enhance drug transport to site-specific tissues.
- the design of prodrugs to date has been to increase the effective water solubility of the therapeutic compound for targeting to regions where water is the principal solvent. See, e.g., Fedorak et al, Am. J. Physiol., 269:G210-218 (1995); McLoed et al., Gastroenterol, 106:405-413 (1994); Hochhaus et al., Biomed. Chrom., 6:283-286 (1992); J. Larsen and H. Bundgaard, Int. J. Pharmaceutics, 37, 87 (1987); J.
- prodrug derivatives of compounds of Formula (1) can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985).
- appropriate prodrugs can be prepared by reacting a non-derivatized compound of Formula (1) with a suitable carbamylating agent, such as, but not limited to, 1 , 1 - acyloxyalkylcarbanochloridate, para-nitrophenyl carbonate, or the like.
- Prodrug forms of the herein described compounds, wherein the prodrug is metabolized in vivo to produce a derivative as set forth herein are included within the scope of the claims. Indeed, some of the herein- described compounds may be a prodrug for another derivative or active compound.
- Sites on the aromatic ring portion of compounds of Formula (1) can be susceptible to various metabolic reactions, therefore incorporation of appropriate substituents on the aromatic ring structures, such as, by way of example only, halogens can reduce, minimize or eliminate this metabolic pathway.
- the compounds described herein may be labeled isotopically (e.g.
- the compounds of Formula (1) may possess one or more chiral centers and each center may exist in the R or S configuration.
- the compounds presented herein include all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof.
- Compounds of Formula (1) can be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers.
- enantiomers can be carried out using covalent diastereomeric derivatives of the compounds described herein, dissociable complexes are preferred (e.g., crystalline diastereomeric salts).
- Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities.
- the diastereomers can be separated by chiral chromatography, or preferably, by separation/resolution techniques based upon differences in solubility.
- the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
- compositions and formulations described in this section and other parts herein use a single formula, such as "Formula (I)," by way of example.
- the pharmaceutical compositions and formulations described herein apply equally well to all formulas presented herein that fall within the scope of Formula (A).
- the pharmaceutical compositions and formulations described herein can be applied to compounds having the structure of Formula (B), Formula (C), Formula (E), Formula (F), Formula (G), Formula (H), Formula (I), Formula (J), Formula (K), Formula (1), Formula (2), Formula (4),
- a pharmaceutical composition refers to a mixture of a compound of Formula (1) with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.
- the pharmaceutical composition facilitates administration of the compound to an organism.
- Pharmaceutical composition containing compounds of Formula (1) can be administered in therapeutically effective amounts as pharmaceutical compositions by any conventional form and route known in the art including, but not limited to: intravenous, oral, rectal, aerosol, parenteral, ophthalmic, pulmonary, transdermal, vaginal, otic, nasal, and topical administration.
- pharmaceutical composition containing compounds of Formula (1) in a targeted drug delivery system, for example, in a liposome coated with organ-specific antibody. The liposomes will be targeted to and taken up selectively by the organ.
- the pharmaceutical composition containing compounds of Formula (1) may be provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of an intermediate release formulation.
- compounds of Formula (1) can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers or excipients well known in the art.
- Such carriers enable the compounds described herein to be formulated as tablets, powders, pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
- Pharmaceutical preparations for oral use can be obtained by mixing one or more solid excipient with one or more of the compounds described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as: for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as: polyvinylpyrrolidone (PVP or povidone) or calcium phosphate.
- disintegrating agents may be added, such as the cross-linked croscarniellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- Dragee cores are provided with suitable coatings.
- suitable coatings For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added.
- AU formulations for oral administration should be in dosages suitable for such administration.
- compositions may take the form of tablets, lozenges, or gels formulated in conventional manner.
- Parental injections may involve for bolus injection or continuous infusion.
- the pharmaceutical composition of Formula (1) may be in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions.
- Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
- Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
- the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- the compounds of Formula (1) can be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams or ointments. Such pharmaceutical compounds can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
- Formulations suitable for transdermal administration of compounds having the structure of Formula (1) may employ transdermal delivery devices and transdermal delivery patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
- transdermal delivery of the compounds of Formula (1) can be accomplished by means of iontophoretic patches and the like. Additionally, transdermal patches can provide controlled delivery of the compounds Formula (1). The rate of absorption can be slowed by using rate-controlling membranes or by trapping the compound within a polymer matrix or gel. Conversely, absorption enhancers can be used to increase absorption. An absorption enhancer or carrier can include absorbable pharmaceutically acceptable solvents to assist passage through the skin.
- transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
- the compounds of Formula (1) maybe in a form as an aerosol, a mist or a powder.
- Pharmaceutical compositions of Formula (1) are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of, such as, by way of example only, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or
- the compounds of Formula (1) may also be formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG, and the like.
- rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas
- conventional suppository bases such as cocoa butter or other glycerides
- synthetic polymers such as polyvinylpyrrolidone, PEG, and the like.
- Li suppository forms of the compositions a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter is first melted.
- therapeutically effective amounts of compounds of Formula (1) provided herein are administered in a pharmaceutical composition to a mammal having a disease or condition to be treated.
- the mammal is a human.
- a therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors.
- the compounds can be used singly or in combination with one or more therapeutic agents as components of mixtures.
- Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- phrases comprising a compound of Formula (1) may be manufactured in a conventional manner, such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
- the pharmaceutical compositions will include at least one pharmaceutically acceptable carrier, diluent or excipient and a compound of Formula (1) described herein as an active ingredient in free-acid or free-base form, or in a pharmaceutically acceptable salt form.
- compositions described herein include the use of N- oxides, crystalline forms (also known as polymorphs), as well as active metabolites of these compounds having the same type of activity.
- compounds may exist as tautomers. All tautomers are included within the scope of the compounds presented herein.
- compositions can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
- the solvated forms of the compounds presented herein are also considered to be disclosed herein.
- the pharmaceutical compositions may include other medicinal or pharmaceutical agents, carriers, adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure, and/or buffers.
- the pharmaceutical compositions can also contain other therapeutically valuable substances.
- Methods for the preparation of compositions comprising the compounds described herein include formulating the compounds with one or more inert, pharmaceutically acceptable excipients or carriers to form a solid, semi-solid or liquid.
- Solid compositions include, but are not limited to, powders, tablets, dispersible granules, capsules, cachets, and suppositories.
- Liquid compositions include solutions in which a compound is dissolved, emulsions comprising a compound, or a solution containing liposomes, micelles, or nanoparticles comprising a compound as disclosed herein.
- Semi-solid compositions include, but are not limited to, gels, suspensions and creams. The compositions may be in liquid solutions or suspensions, solid forms suitable for solution or suspension in a liquid prior to use, or as emulsions. These compositions may also contain minor amounts of nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and so forth.
- compositions, uses and methods described in this section and other parts herein use a single formula, such as "Formula (I)," by way of example.
- Formula (A) including compounds having the structure of Formula (B), Formula (C), Formula (E), Formula (F), Formula (G), Formula (H), Formula (I), Formula (J), Formula (K), Formula (1), Formula (2), Formula (4), Formula (5), Formula (6), as well as to all of the specific compounds that fall within the scope of these generic formula.
- the compounds of Formula (1) can be used in the preparation of medicaments for the treatment of diseases or conditions in which steroid hormone nuclear receptor activity contributes to the pathology and/or symptomology of the disease.
- a method for treating any of the diseases or conditions described herein in a subject in need of such treatment involves administration of pharmaceutical compositions containing at least one compound of Formula (1), or a pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, in therapeutically effective amounts to said subject [00137]
- the compositions containing the compound(s) described herein can be administered for prophylactic and/or therapeutic treatments.
- compositions are administered to a patient already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest the symptoms of the disease or condition. Amounts effective for this use will depend on the severity and course of the disease or condition, previous therapy, the patient's health status, weight, and response to the drugs, and the judgment of the treating physician. It is considered well within the skill of the art for one to determine such therapeutically effective amounts by routine experimentation (including, but not limited to, a dose escalation clinical trial).
- compositions containing the compound(s) described herein can be used to treat a disease-state or condition selected from: arteriosclerosis, neurological diseases, cancer, Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Barter's Syndrome, congestive heart failure (CHF), conditions associated with excess catecholamine levels, cognitive dysfunctions, psychoses, cognitive conditions, memory disturbances, mood conditions, depression, bipolar condition , anxiety conditions, personality conditions, inflammation, tissue rejection, auto-immunity, malignancies such as leukemias and lymphomas, Cushing's syndrome, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granul
- the administration of the compounds may be administered chronically, that is, for an extended period of time, including throughout the duration of the patient's life in order to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition.
- the administration of the compounds may be given continuously or temporarily suspended for a certain length of time ⁇ i.e., a "drug holiday").
- a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, can be reduced, as a function of the symptoms, to a level at which the improved disease or condition is retained. Patients can, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms.
- the compounds described herein may be administered therapeutically effective amounts of at least one of the compounds described herein (or a pharmaceutically acceptable salts, pharmaceutically acceptable N-oxides, pharmaceutically active metabolites, pharmaceutically acceptable prodrugs, and pharmaceutically acceptable solvates thereof) in combination with another therapeutic agent.
- a pharmaceutically acceptable salts, pharmaceutically acceptable N-oxides, pharmaceutically active metabolites, pharmaceutically acceptable prodrugs, and pharmaceutically acceptable solvates thereof in combination with another therapeutic agent.
- an adjuvant i.e., by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced.
- the benefit of experienced by a patient may be increased by administering one of the compounds described herein with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit, hi any case, regardless of the disease or condition being treated, the overall benefit experienced by the patient may simply be additive of the two therapeutic agents or the patient may experience a synergistic benefit.
- another therapeutic agent which also includes a therapeutic regimen
- synergistic effects can occur with compounds of Formula (1) and other substances used in the treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart disease, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction.
- anti-obesity agents such as orlistat, anti-hypertensive agents, inotropic agents and hypolipidemic agents including, but not limited to,, loop diuretics, such as ethacrynic acid, furosemide and torsemide
- loop diuretics such as ethacrynic acid, furosemide and torsemide
- angiotensin converting enzyme (ACE) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perinodopril, quinapril, ramipril and trandolepril
- inhibitors of the Na-K- ATPase membrane pump such as digoxin
- ACE/NEP inhibitors such as omapatrilat, sampatrilat, and fasidotril
- dosages of the co-administered compounds will of course vary depending on the type of co-drug employed, on the specific drug employed, on the disease or condition being treated and so forth.
- the compound provided herein may be administered either simultaneously with the biologically active agent(s), or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein in combination with the biologically active agent(s).
- the multiple therapeutic agents may be administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may vary from more than zero weeks to less than four weeks.
- the combination methods, compositions and formulations are not to be limited to the use of only two agents; we envision the use of multiple therapeutic combinations
- the compounds of Formula (1) may also be used in combination with procedures that may provide additional or synergistic benefit to the patient.
- patients are expected to find therapeutic and/or prophylactic benefit in the methods described herein, wherein pharmaceutical composition of Formula (1) and /or combinations with other therapeutics are combined with genetic testing to determine whether that individual is a carrier of a mutant gene that is known to be correlated with certain diseases or conditions.
- the compounds of Formula (1) and combination therapies can be administered before, during or after the occurrence of a disease or condition, and the timing of administering the composition containing a compound can vary.
- the compounds can be used as a prophylactic and can be administered continuously to subjects with a propensity to conditions or diseases in order to prevent the occurrence of the disease or condition.
- the compounds and compositions can be administered to a subject during or as soon as possible after the onset of the symptoms.
- the administration of the compounds can be initiated within the first 48 hours of the onset of the symptoms, preferably within the first 48 hours of the onset of the symptoms, more preferably within the first 6 hours of the onset of the symptoms, and most preferably within 3 hours of the onset of the symptoms.
- the initial administration can be via any route practical, such as, for example, an intravenous injection, a bolus injection, infusion over 5 minutes to about 5 hours, a pill, a capsule, transdermal patch, buccal delivery, and the like, or combination thereof.
- a compound is preferably administered as soon as is practicable after the onset of a disease or condition is detected or suspected, and for a length of time necessary for the treatment of the disease, such as, for example, from about 1 month to about 3 months.
- the length of treatment can vary for each subject, and the length can be determined using the known criteria.
- the compound or a formulation containing the compound can be administered for at least 2 weeks, preferably about 1 month to about 5 years, and more preferably from about 1 month to about 3 years.
- the pharmaceutical composition described herein may be in unit dosage forms suitable for single administration of precise dosages.
- the formulation is divided into unit doses containing appropriate quantities of one or more compound.
- the unit dosage may be in the form of a package containing discrete quantities of the formulation.
- Non- limiting examples are packaged tablets or capsules, and powders in vials or ampoules.
- Aqueous suspension compositions can be packaged in single-dose non-reclosable containers.
- multiple-dose reclosable containers can be used, in which case it is typical to include a preservative in the composition.
- formulations for parenteral injection may be presented in unit dosage form, which include, but are not limited to ampoules, or in multi-dose containers, with an added preservative.
- the daily dosages appropriate for the compounds of Formula (1) described herein are from about 0.03 to 2.5 mg/kg per body weight.
- An indicated daily dosage in the larger mammal, including, but not limited to, humans, is in the range from about 0.5 mg to about 100 mg, conveniently administered in divided doses, including, but not limited to, up to four times a day or in retard form.
- Suitable unit dosage forms for oral administration comprise from about 1 to 50 mg active ingredient.
- Such dosages may be altered depending on a number of variables, not limited to the activity of the compound used, the disease or condition to be treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated, and the judgment of the practitioner.
- Toxicity and therapeutic efficacy of such therapeutic regimens can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between the toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD 50 and ED 50 .
- Compounds exhibiting high therapeutic indices are preferred.
- kits and articles of manufacture are also described herein.
- Such kits can comprise a carrier, package, or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in a method described herein.
- Suitable containers include, for example, bottles, vials, syringes, and test tubes.
- the containers can be formed from a variety of materials such as glass or plastic.
- the container(s) can comprise one or more compounds described herein, optionally in a composition or in combination with another agent as disclosed herein.
- the container(s) optionally have a sterile access port (for example the container can be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
- kits optionally comprising a compound with an identifying description or label or instructions relating to its use in the methods described herein.
- a kit will typically may comprise one or more additional containers, each with one or more of various materials (such as reagents, optionally in concentrated form, and/or devices) desirable from a commercial and user standpoint for use of a compound described herein.
- materials include, but not limited to, buffers, diluents, filters, needles, syringes; carrier, package, container, vial and/or tube labels listing contents and/or instructions for use, and package inserts with instructions for use.
- a set of instructions will also typically be included.
- a label can be on or associated with the container.
- a label can be on a container when letters, numbers or other characters forming the label are attached, molded or etched into the container itself; a label can be associated with a container when it is present within a receptacle or carrier that also holds the container, e.g., as a package insert.
- a label can be used to indicate that the contents are to be used for a specific therapeutic application. The label can also indicate directions for use of the contents, such as in the methods described herein.
- the dibenzosuberenone compound can be synthesized by the following procedure. To a stirred solution of 5H-Dibenzo[a,d]cyclohepten-5-one (10 g, 48 mmol) and iodine (5 mol%) in dichloromethane (DCM) (60 mL), TMSCN (8.0 niL, 60 mmol) is added slowly at 0 0 C and the mixture allowed to stir at room temperature for 1 hour. The reaction is quenched with saturated sodium thiosulfate (Na 2 S 2 O 3 ) solution and most of the DCM removed. The residue is extracted with ethyl aceate (EtOAc) and the aqueous layer separated.
- DCM dichloromethane
- EtOAc ethyl aceate
- the dibenzosuberone compound can be synthesized by the following procedure. To a stirred solution of 10,1 l-dihydro-5H- Dibenzo[a,d]cyclohepten-5-one (4.1 g, 19.7 mmol) and iodine (5 mol%) in DCM (60 mL), TMSCN (2.7 mL, 20 mmol) is added slowly at 0 °C and the mixture stirred at 90 °C for 12 hours. The reaction mixture is cooled, quenched with saturated Na 2 S 2 O 3 solution and most of the DCM removed. The residue is extracted with EtOAc and the aqueous layer separated. The organic layer is washed with brine, dried over MgSO4 and filtered.
- Fused-ring spiro compounds can be obtained by cyclocondensation of a ketoacid with amino-alcohol intermediates, such as compounds 3 a or 3b, in a suitable refluxing solvent using a Dean-Stark trap (see scheme 7 and scheme 8).
- a solution of a starting intermediate, such as compounds 3a or 3b, (HCl salt, 1.0 mol equiv) and a ketoacid (1.0-1.5 mol equiv) in toluene (25 ml) are refluxed using the Dean-Stark apparatus, with the progress of the reaction being monitored by analytical TLC until completion within about 8 to 12 hours. After cooling to room temperature the toluene is removed and the crude product purified.
- Fused-ring spiro- dibenzosuberenone compounds FRS-I through FRS-14 are synthesized according to scheme 7 and scheme 8, as described below.
- Compound FRS-I is prepared from compound 3a (1. Ig, 4.8 mmol) and 4-oxo- pentanoic acid (0.5 mL, 4.9 mmol) according to scheme 7 and scheme 8.
- the crude product is triturated in hexane-diethyl ether (Et 2 O) (4: 1 v/v) and the solid filtered to afford the title compound as a white solid:
- Chirally pure FRS-I is obtained by synthesis using chiral HPLC using the following conditions: Column and Dimensions: Whelk-01 10/100 25cmx4.6mm ID, flow Rate: lmL/min, sample concentration: lmg/mL dissolved in MeOH, sample Run Time: 45 minutes, solvent conditions: 30% Isopropanol and 70% Hexanes wavelength monitored: 220nm.
- Compound FRS-2 is prepared from compound 3a (0.5 g, 2.1 mmol) and 4-oxo-4- phenyl-butyric acid (0.38 g, 2.1 mmol) according to scheme 7 and scheme 8. The crude product is triturated in Et 2 O and the solid filtered to afford the title compound as a white solid: MS (ESI) m/z 380 [M+H] + .
- Compound FRS-3 is prepared from compound 6a (0.5 g, 2.1 mmol) and 4-(4-fiuoro- phenyl)-4-oxo-butyric acid (0.4 g, 2.1 mmol) according to scheme 7 and scheme 8. The crude product is triturated in Et 2 O and the solid filtered to afford the title compound as a white solid: MS (ESI) m/z 398 [M+H] + .
- Example 3d Synthesis of Compound FRS-4
- Compound FRS-5 is prepared from compound 3a (0.2 g, 0.73 mmol) and 4-(4- methoxy-phenyl)-4-oxo-butyric acid (0.16 g, 0.77 mmol) according to scheme 7 and scheme ⁇
- the crude product is triturated in Et 2 O and the solid filtered to afford the title compound as a white solid: MS (ESI) m/z 410 [M+H] + .
- Compound FRS-6 is prepared from compound 3a (0.1 g, 0.37 mmol) and 6-oxo- heptanoic acid (55 mg, 0.38 mmol) according to scheme 7 and scheme 8. The crude product is purified by HPLC (10% CH 3 CN/water to 90% CH 3 CN/water in 7 min) to afford the title compound as a white solid: MS (ESI) m/z 346 [M+H] + .
- Example 3 g Synthesis of Compound FRS-7
- Compound FRS-7 is prepared from compound 3a (0.1 g, 0.37 mmol) and 4-(4- bromo-phenyl)-4-oxo-butyric acid (95 mg, 0.37 mmol) according to scheme 7 and scheme 8. The crude product is triturated in hexane-Et2 ⁇ (4: 1 v/v) and the solid filtered to afford the title compound as a white solid: MS (ESI) m/z 459 [M+H] + .
- Example 3h Synthesis of Compound FRS-8
- Example 3i Synthesis of Compound FRS-9
- Compound FRS-9 is prepared from compound 3a (0.1 g, 0.37 mmol) and 4-oxo- heptanoic acid (53 mg, 0.37 mmol) according to scheme 7 and scheme 8. The crude product is triturated in hexane-Et2 ⁇ (5:1 v/v) and the solid filtered to afford the title compound as an off white solid: MS (ESI) m/z 346 [M+H] + .
- Compound FRS-10 is prepared from compound 3a (l.lg, 4.8 mmol) and 4-oxo-4- cyclopropyl-2-yl-butyric acid (0.5 mL, 4.9 mmol) according to scheme 7 and scheme 8.
- the crude product is purified by HPLC (10% CH 3 CN/water to 90% CH 3 CN/water in 7 min).to afford the title compound as a white solid: MS (ESI) m/z 344 [M+H] + .
- Example 3k Synthesis of Compound FRS-11
- Compound FRS-Il is prepared from compound 3a (250 mg, 0.91 mmol) and 4-oxo- 4-triflfuoromethyl-2-yl-butyric acid (0.1 mL, 0.92 mmol) according to scheme 7 and scheme 8. The crude product is purified by HPLC (10% CH 3 CN/water to 90% CH 3 CN/water in 7 minutes) to afford the title compound as a white solid: MS (ESI) m/z 386 [M+H] + .
- Example 31 Synthesis of Compound FRS-12
- Compound FRS-12 is prepared from compound 3a (237 mg, 0.8 mmol) and 4-oxo-4- [3-(N-phenylsulfonyl)pyrrole]-2-yl-butyric acid (0.1 niL, 1 mmol) according to scheme 7 and scheme 8.
- the crude product purified by HPLC (10% CH 3 C ⁇ /water to 90% CH 3 CN/water in 7 min).to afford the title compound as a white solid: MS (ESI) m/z 509 [M+H] + .
- Example 3m Synthesis of Compound FSR- 13
- Compound FRS-13 is prepared from compound 3b (0.7 g, 2.9 mmol) and 4-oxo- pentanoic acid (0.3 mL, 2.9 mmol) according to scheme 7 and scheme 8. The crude product is triturated in hexane-Et 2 O (4:1 v/v) and the solid filtered to afford the title compound as a white solid: MS (ESI) m/z 320 [M+H] + .
- Chirally pure FRS-13 is obtained by synthesis using chiral HPLC using the following conditions: Column and Dimensions: Whelk-01 10/100 25cmx4.6mm ID, flow Rate: lmL/min, sample concentration: lmg/mL dissolved in MeOH, sample Run Time: 45 minutes, solvent conditions: 30% Isopropanol and 70% Hexane wavelength monitored: 220nm
- Example 3n Synthesis of Compound FSR- 14
- Compound FSR-14 is prepared from compound 3b (0.7 g, 2.9 mmol) and 5-oxo- hexanoic acid (0.35 mL, 2.9 mmol) according to scheme 7 and scheme 8. The crude product is triturated in hexane-Et 2 O (4:1 v/v) and the solid filtered to afford the title compound as an off white solid: MS (ESI) m/z 334 [M+H] + .
- Oxazoline spiro- compounds of Formula (G) may be synthesized by reaction of amino-alcohol compounds of Formula (D) with imidate compounds according to Scheme 9.
- oxazoline spiro-dibenzosuberenone, or oxazoline spiro-dibenzosuberone compounds, of Formula (6) may be synthesized by reaction of amino-alcohol compounds (3a) or (3b), respectively, with imidate compounds according Scheme 10.
- synthesis of oxazoline spiro-dibenzosuberenone compounds OXS-I through OXS-3 is described below.
- Example 4a Synthesis of Compound OXS-I
- Oxazolidine spiro- compounds of Formula (E) may be synthesized by reaction of amino-alcohol compounds of Formula (D) with ketone compounds according to Scheme 11.
- oxazolidine spiro-dibenzosuberenone, or oxazolidine spiro-dibenzosuberone compounds, of Formula (4) maybe synthesized by reaction of amino-alcohol compounds (3a) or (3b), respectively, with ketone compounds according Scheme 12.
- synthesis of oxazolidine spiro-dibenzosuberenone compounds BOXS-I and BOXS-2 is described below.
- Example 5a Synthesis of Compound BOXS-I
- Compound BOXS-I is prepared from compound 3a; wherein a solution of compound 3a (1.0 g, 3.7 mmol) in acetone (20 mL) is heated at reflux for 12 h. The resulting solution is cooled and the solvent removed. The residue is triturated in hexane and the solid filtered. The filtrate is concentrated and the crude product purified by flash chromatography on silica gel
- Compound BOXS-2 is prepared from compound 3 a; wherein to a solution of compound 3a (0.55 g, 2.3 mmol) in 1,2-dichloroethane (10 mL) is added cyclohexanone (4.0 mL, 39 mmol) and TsOH (5 mol%). The mixture is heated at 80 0 C for 12 h. The resulting mixture is cooled and the solvent removed.
- Substituted oxazolidine spiro- compounds of Fonnula may be synthesized by reaction of oxazolidine spiro- compounds of Formula (E) with an electrophilic reactant according to Scheme 11.
- substituted oxazolidine spiro-dibenzosuberenone, or substituted oxazolidine spiro-dibenzosuberone compounds, of Formula (5) may be synthesized by reaction of oxazolidine spiro- compounds of Formula (4), with an electrophilic reactant according
- Compound SOXS-I is prepared from a solution of a compound BOXS-I (50 mg, 0.18 mmol) and 2,4-difluorophenyl isocyanate (0.02 mL, 0.18 mmol) in DCM (4 mL) which is stirred at room temperature for 2 hours. The resulting mixture is concentrated and the residue triturated in hexane.
- Compound SOXS-2 is synthesized from a solution of a compound BOXS-I (30 mg, 0.16 mmol) and 3,5-dimethylisoxazole isocyanate (0.02 mL, 0.18 mniol) in DCM (4 mL) which is stirred at room temperature for 2 hours. After removal of the solvents under reduced pressure, the crude product is purified by HPLC (10% CH 3 CN/water to 90% CH 3 CN/water in 7 min) to afford the title compound as a white solid: MS (ESI) m/z 456 [M+H] + .
- Example 6c Synthesis of Compound SOXS-3
- Compound SOXS-3 is synthesized from a solution of a compound BOXS-I , wherein to a solution of a compound BOXS-I (50.0 mg, 0.18 mmol) in dichloromethane (2 ml) and JV 1 N- di ⁇ opropyl amine (0.2 ml) is added acetyl chloride (0.015 ml, 0.3 mmol) at room temperature. The mixture is stirred at RT for 2 h, diluted with EtOAc and washed with saturated aqueous Na 2 CO 3 and brine, then dried over MgSO 4 .
- Compound SOXS-4 is synthesized from a solution of a compound BOXS-I , wherein to a solution of a compound BOXS-I (50.0 mg, 0.18 mmol) in dichloromethane (2 ml) and N 1 N- dizsopropyl amine (0.2 ml) is added methanesulfonyl chloride (0.015 ml, 0.3 mmol) at room temperature. The mixture is stirred at room temperature for 2 hours, diluted with EtOAc and washed with saturated aqueous Na 2 CO 3 and brine, then dried over MgSO 4 .
- Compound SOXS-5 is synthesized from a solution of a compound BOXS- 1 ; wherein to a solution of a compound BOXS-I (50.0 mg, 0.18 mmol) in dichloromethane (2 ml) and ⁇ N- di ⁇ opropyl amine (0.2 ml) is added benzoyl chloride (0.02 ml, 0.3 mmol) at room temperature. The mixture is stirred at room temperature for 2 hours, diluted with EtOAc and washed with saturated aqueous Na 2 CO 3 and brine, then dried over MgSO 4 .
- Compound SOXS-6 is synthesized from a solution of a compound BOXS-2; wherein to a solution of a compound BOXS-2 (50.0 mg, 0.18 mmol) in dichloromethane (2 ml) and N 1 N- dizsopropyl amine (0.2 ml) is added acetyl chloride (0.01 ml, 0.3 mmol) at room temperature. The mixture is stirred at room temperature for 2 hours, diluted with EtOAc and washed with saturated aqueous Na 2 CO 3 and brine, then dried over MgSO 4 .
- Compound SOXS-7 is synthesized from a solution of a compound BOXS-3 as described for the synthesis of SOXS-6.
- Example 7 Pharmaceutical Compositions
- Example 7a Parenteral Composition
- a parenteral pharmaceutical composition suitable for administration by injection 100 mg of a water-soluble salt of a compound of Formula (1) is dissolved in DMSO and then mixed with 10 mL of 0.9% sterile saline. The mixture is incorporated into a dosage unit form suitable for administration by injection.
- MR antagonist activity of the compounds is determined in a mammalian two hybrid reporter system.
- the N-terminus of MR (MR-NT, sequence coding amino acid 1-597) is fused to the activation domain of the VP 16 gene.
- the ligand binding domain of MR (MR-LBD, sequence encoding amino acid 672-984) is fused to the DNA binding domain of the yeast Gal4 gene.
- the MR gene is cloned from a human kidney cDNA library with PCR.
- the assay is performed in 384 well plates. Briefly, 293T cells (ATCC) are transfected with expression vectors for Gal4-MR-LBD and VP 16-MR NT, and a luciferase reporter vector containing Gal4 binding sequence ( ⁇ G5-Luc). Cells are plated in 384 well plates immediately after transfection (approximately 3 x 10 4 cells/well in 50 ⁇ l medium). The medium is supplemented with 3% charcoal-dextran treated fetal bovine serum (Hyclone). Twenty four hours after transfection, compounds prepared in DMSO are transferred to the cells.
- the GR antagonist activity of the compounds is determined in a mammalian two hybrid reporter system.
- the ligand binding domain of GR (GR-LBD, sequence encoding amino acid 541-778) is fused to the DNA binding domain of the yeast Gal4 gene.
- the GR gene is cloned from a human lung cDNA library with PCR.
- the assay is performed in 384 well plates: COS-7 cells (ATCC) are transfected with expression vectors for GaW-GR-LBD and a luciferase reporter vector containing Gal4 binding sequence (pG5-Luc). Cells are plated in 384 well plates immediately after transfection (approximately 8000 cells/well in 50 ⁇ l medium).
- the medium is supplemented with 3% charcoal-dextran treated fetal bovine serum (Hyclone).
- compounds prepared in DMSO are transferred to the cells.
- the cells are then stimulated with 10 nM final concentration of dexamethasone (Sigma) and incubated at 37°C for another 24 hours before the luciferase activity is assayed with 20 ⁇ l of Bright-Glo (Promega) using a luminometer (CLIPR).
- CLIPR luminometer
- the expression of luciferase is used as an indicator of dexamethasone-induced GR trans-activation.
- Each compound is tested in duplicates with a 12-concentration titration.
- IC 50 values (defined as the concentration of test compound required to antagonize 50% of dexamethasone-induced GR activity) are determined from the dose-response curve.
- Example 10 Functional Assay of Progesterone Receptor Antagonism
- the PR antagonist activity of the compounds is determined by progesterone-induced alkaline phosphatase activity in the T-47D cell line (ATCC). In the T-47D breast cancer cells, progesterone specifically induces de novo synthesis of a membrane-associated alkaline phosphatase enzyme in a time and dose-dependent manner (Di Lorenzo et al., Cancer Research, 51: 4470-4475 (1991)).
- the alkaline phosphatase enzymatic activity can be measured with a chemiluminescent substrate, such as CSPD ® (Applied Biosystems).
- a chemiluminescent substrate such as CSPD ® (Applied Biosystems).
- the assay is performed in 384 well plates. Briefly, T-47D cells are plated in 384 well plates at a density of approximately 2.5 x 10 4 cells/well in 50 ⁇ l medium supplemented with 10% fetal bovine serum. Twenty four hours later, the medium is aspirated. New medium that is free of phenol red and serum is added to the cells. Compounds prepared in DMSO are transferred to the cells.
- the cells are then stimulated with 3 nM final concentration of progesterone (Sigma) and incubated at 37°C for another 24 hours before the alkaline phosphatase is assayed with 25 ⁇ l of CSPD ® (Applied Biosystems) using a luminometer (CLIPR).
- the expression of alkaline phosphatase is used as an indicator of progesterone-induced PR trans-activation.
- IC 50 values (defined as the concentration of test compound required to antagonize 50% of progesterone-induced PR activity) are determined from the dose-response curve.
- Example 11 Functional Assay of Androgen Receptor Antagonism
- the AR antagonist activity of the compounds is determined with the MDA-Kb2 cell line (ATCC), which stably expresses the MMTV luciferase reporter.
- the MMTV promoter is a mouse mammary tumor virus promoter that contains androgen receptor response elements.
- the MDA-kb2 cells is derived from the MDA-MB-453 cells, which has been shown to express high levels of functional, endogenous androgen receptor (Wilson et al., Toxicological Sciences, 66: 69-81 (2002)).
- AR ligands such as dihydrotestosterone
- the assay is performed in 384 well plates. Briefly, MDA-kb2 cells are plated in 384 well plates at a density of approximately 2.4 x 10 4 cells/well in 50 ⁇ l medium. The medium is supplemented with 5% charcoal-dextran treated fetal bovine serum (Hyclone). Twenty four hours later, compounds prepared in DMSO are transferred to the cells. The cells are then stimulated with 0.3 nM final concentration of dihydrotestosterone (Sigma) and incubated at 37°C for another 24 hours before the luciferase activity is assayed with 20 ⁇ l of Bright-Glo (Promega) using a luminometer (CLIPR).
- CLIPR luminometer
- luciferase is used as an indicator of dihydrotestosterone-induced AR trans-activation. Each compound is tested in duplicates with a 12-concentration titration. IC 50 values (defined as the concentration of test compound required to antagonize 50% of dihydrotestosterone-induced AR activity) are determined from the dose- response curve.
- test compounds were evaluated using the functional assays described above for the different steroid hormone nuclear receptors.
- the ability of exemplary test compounds to antagonize 50% of the specified steroid hormone nuclear receptor is shown in Table 2 as a range of IC 50 values.
- Table 2 Ranges of ICsn values for test compounds required to antagonize 50% of the specified steroid hormone nuclear receptor.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06758162A EP1850844A4 (en) | 2005-02-25 | 2006-02-16 | Spiro-containing compounds and compositions as modulators of steroid hormone nuclear receptors |
US11/816,097 US7807841B2 (en) | 2005-02-25 | 2006-02-16 | Spiro-containing compounds and compositions as modulators of steroid hormone nuclear receptors |
AU2006229672A AU2006229672B8 (en) | 2005-02-25 | 2006-02-16 | Spiro-containing compounds and compositions as modulators of steroid hormone nuclear receptors |
BRPI0607768-4A BRPI0607768A2 (en) | 2005-02-25 | 2006-02-16 | spiro-containing compounds and compositions as modulators of steroid hormone nuclear receptors, method for the preparation of said compounds, related uses, as well as methods for modulating the activity of at least one nuclear steroid hormone receptor |
MX2007010318A MX2007010318A (en) | 2005-02-25 | 2006-02-16 | Spiro-containing compounds and compositions as modulators of steroid hormone nuclear receptors. |
JP2007557074A JP2008531564A (en) | 2005-02-25 | 2006-02-16 | Spiro-containing compounds and compositions as modulators of steroid hormone nuclear receptors |
CA002598878A CA2598878A1 (en) | 2005-02-25 | 2006-02-16 | Spiro-containing compounds and compositions as modulators of steroid hormone nuclear receptors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65686105P | 2005-02-25 | 2005-02-25 | |
US60/656,861 | 2005-02-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006104594A2 true WO2006104594A2 (en) | 2006-10-05 |
WO2006104594A3 WO2006104594A3 (en) | 2007-11-22 |
Family
ID=37053845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/005803 WO2006104594A2 (en) | 2005-02-25 | 2006-02-16 | Spiro-containing compounds and compositions as modulators of steroid hormone nuclear receptors |
Country Status (11)
Country | Link |
---|---|
US (1) | US7807841B2 (en) |
EP (1) | EP1850844A4 (en) |
JP (1) | JP2008531564A (en) |
KR (1) | KR100898840B1 (en) |
CN (1) | CN101287717A (en) |
AU (1) | AU2006229672B8 (en) |
BR (1) | BRPI0607768A2 (en) |
CA (1) | CA2598878A1 (en) |
MX (1) | MX2007010318A (en) |
RU (1) | RU2007135273A (en) |
WO (1) | WO2006104594A2 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3138608A (en) * | 1962-06-21 | 1964-06-23 | American Home Prod | Spiro-oxazolidinedione derivatives |
JPH04225953A (en) * | 1990-05-07 | 1992-08-14 | Shionogi & Co Ltd | Spiro dibenzosuberane derivative |
US6723714B2 (en) * | 1999-07-06 | 2004-04-20 | Blansett Pharmacal Co., Inc. | Aqueous solvent for corticosteroids |
AU6729600A (en) * | 1999-08-25 | 2001-03-19 | Banyu Pharmaceutical Co., Ltd. | Novel isoindole derivatives |
EP1487792A1 (en) | 2002-03-15 | 2004-12-22 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
TW200400816A (en) * | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
-
2006
- 2006-02-16 WO PCT/US2006/005803 patent/WO2006104594A2/en active Application Filing
- 2006-02-16 EP EP06758162A patent/EP1850844A4/en not_active Withdrawn
- 2006-02-16 US US11/816,097 patent/US7807841B2/en not_active Expired - Fee Related
- 2006-02-16 RU RU2007135273/04A patent/RU2007135273A/en not_active Application Discontinuation
- 2006-02-16 BR BRPI0607768-4A patent/BRPI0607768A2/en not_active IP Right Cessation
- 2006-02-16 MX MX2007010318A patent/MX2007010318A/en not_active Application Discontinuation
- 2006-02-16 KR KR1020077019383A patent/KR100898840B1/en not_active IP Right Cessation
- 2006-02-16 CN CNA2006800061136A patent/CN101287717A/en active Pending
- 2006-02-16 AU AU2006229672A patent/AU2006229672B8/en not_active Ceased
- 2006-02-16 JP JP2007557074A patent/JP2008531564A/en active Pending
- 2006-02-16 CA CA002598878A patent/CA2598878A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of EP1850844A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1850844A4 (en) | 2010-05-26 |
CN101287717A (en) | 2008-10-15 |
AU2006229672B2 (en) | 2008-12-11 |
KR100898840B1 (en) | 2009-05-21 |
US7807841B2 (en) | 2010-10-05 |
MX2007010318A (en) | 2007-10-17 |
AU2006229672A1 (en) | 2006-10-05 |
US20090124597A1 (en) | 2009-05-14 |
EP1850844A2 (en) | 2007-11-07 |
BRPI0607768A2 (en) | 2009-10-06 |
AU2006229672B8 (en) | 2009-01-08 |
KR20070107066A (en) | 2007-11-06 |
JP2008531564A (en) | 2008-08-14 |
CA2598878A1 (en) | 2006-10-05 |
RU2007135273A (en) | 2009-03-27 |
WO2006104594A3 (en) | 2007-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1865775A1 (en) | Diarylamine-containing compounds and compositions, and their use as modulators of steroid hormone nuclear receptors | |
ES2325861T3 (en) | TRICYCLE MODULATORS OF NUCLEAR RECEPTORS OF STEROID HORMOSAS. | |
WO2007084314A2 (en) | MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | |
JP2010518026A (en) | Pyridopyrimidinone compounds useful for the treatment of diseases or conditions mediated by sodium channels | |
US20170008920A1 (en) | Mammalian metabolites of steroids | |
JPWO2008096829A1 (en) | Tricyclic compounds | |
AU2007333021A1 (en) | Terephthalamate compounds and compositions, and their use as HIV integrase inhibitors | |
KR100502880B1 (en) | Benzothiadiazoles and Derivatives | |
CA3170664A1 (en) | P2x3 modulators | |
AU2017326297B2 (en) | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | |
TW201124391A (en) | 2-substituted-ethynylthiazole derivatives and uses of same | |
WO2005018573A2 (en) | 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds | |
WO2012073146A1 (en) | Kat ii inhibitors | |
AU2006229672B2 (en) | Spiro-containing compounds and compositions as modulators of steroid hormone nuclear receptors | |
KR20200023362A (en) | 17.Beta .- [3-propaneamido] -substituted estra-1,3,5 (10) -trien-17-one compounds for use as inhibitors of beta.-hydroxysteroid dehydrogenases and 17-oxime | |
CA2976746C (en) | (2r)-3-amino-2-(bicyclic pyridylmethyl)-2-hydroxy-propanoic acid compounds and their use as inhibitors of placental leucine aminopeptidase (p-lap) | |
ES2755476T3 (en) | Pyridine derivatives | |
JPH02221274A (en) | New derivative | |
FR2640975A1 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680006113.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 5934/DELNP/2007 Country of ref document: IN Ref document number: 2006758162 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006229672 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2598878 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/010318 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007557074 Country of ref document: JP Ref document number: 1020077019383 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006229672 Country of ref document: AU Date of ref document: 20060216 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007135273 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11816097 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0607768 Country of ref document: BR Kind code of ref document: A2 |